Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Sep. 30, 2022
Current assets:
Cash, cash equivalents and restricted cash	$ 134,959	$ 108,005
Accounts receivable	69,434	1,410
Short term investments	346,046	268,391
Prepaid expenses	9,935	7,289
Other current assets	14,436	20,204
Total current assets	574,810	405,299
Property and equipment, net	185,228	110,297
Intangible assets, net	11,112	11,962
Long-term investments	78,834	105,872
Right-of-use assets	41,114	58,291
Other assets	210	218
Total Assets	891,308	691,939
Current liabilities:
Accounts payable	9,556	2,868
Accrued expenses	39,551	46,856
Accrued payroll and benefits	5,494	12,251
Lease liabilities	2,711	2,776
Deferred revenue	29,839	74,099
Total current liabilities	87,151	138,850
Long-term liabilities:
Lease liabilities, net of current portion	80,070	78,800
Deferred revenue, net of current portion	1,075	55,950
Liability related to the sale of future royalties	257,906	0
Total long-term liabilities	339,051	134,750
Commitments and Contingencies
Noncontrolling interest and stockholders’ equity:
Common stock, $0.001 par value: Authorized 290,000 and 145,000 shares; issued and outstanding 106,869 and 105,960 shares	199	198
Additional paid-in capital	1,260,310	1,219,213
Accumulated other comprehensive loss	(332)	(136)
Accumulated deficit	(813,405)	(820,755)
Total Arrowhead Pharmaceuticals, Inc. stockholders’ equity	446,772	398,520
Noncontrolling interest	18,334	19,819
Total noncontrolling interest and stockholders’ equity	465,106	418,339
Total Liabilities, Noncontrolling Interest and Stockholders’ Equity	$ 891,308	$ 691,939